When an embattled venture capital investor’s plans have been derailed by budgetary constraints, the stage is set for another backer to step in with the capital to galvanise their portfolio businesses.

A recent example of this is the predicament facing commercialisation firm NetScientific, which has allowed investment firm EMV Capital to pick up two University of California healthcare spinouts, cancer diagnostics provider Vortex Biosciences and chronic disease management company Wanda, for a fraction of their most-recently published market valuations. Having come across the spinouts through its…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.